NCT Number: NCT00038909
Study Evaluating ReFacto in Hemophilia A
To identify the causative mutations in previously untreated patients with hemophilia A enrolled in the ReFacto® clinical safety and efficacy study CTN 93-R833-0XX/C9741-28, using two established hemophilia mutation testing laboratories (one in Europe and one in North America).
Looking for future studies?
Notify MeKey information
Conditions
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Patients who were or are enrolled in Study CTN 93-R833-0XX/C9741-28, and have been treated with ReFacto® during this study are eligible for participation.
- The patient (or legal guardian) must be willing to give written informed consent before any study-related procedures are performed.
- A blood sample will be collected from each patient for the purpose of this study and will be analyzed at one or both of the designated central laboratories.
Exclusion criteria
- Any condition which, in the investigator's opinion, places the patient at undue risk.
Treatment and study plan
Sponsors and collaborators
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Registry information
Official study title
Factor VIII Mutation Testing Program in Previously Untreated Patients (PUPs) With Hemophilia A Participating in ReFacto® Study
Important dates
- Study start
- 1994
- Primary completion
- 2001
- Study completion
- 2001
- First posted
- Jun 7, 2002
- Registry last updated
- Feb 8, 2013
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the Blood
NCT05147662
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited
Orlando, Florida, United States
View Trial DetailsPharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A
NCT06579144
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited
Sofia, Bulgaria
View Trial DetailsEfficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants
NCT03315455
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited
Beijing, China
View Trial DetailsA Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors
NCT04158648
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited
Los Angeles, California, United States
View Trial Details